Evidence map›Paper›PMID 22780885›Full record

Trial reportGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2012

Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome.

Lubna Pal, Amber Berry, Luisa Coraluzzi, Erin Kustan, Cheryl Danton, Julia Shaw, Hugh Taylor

2 registry-linked trialsOpen access · greenAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00743574 nacompletednot on this map

Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)

TypeinterventionalSponsorYale UniversityRan2008 to 2013Enrolled36ConditionsPolycystic Ovarian Syndrome, Vitamin D DeficiencyArmsVitamin D2 (Ergocalciferol), Medroxyprogesterone (Provera), Vitamin D3 (Cholecalciferol), Elemental Calcium
NCT02803476 unknown statusnot on this mapstarted 2016, after this paper: background citation

Is There An Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?

TypeobservationalSponsorAin Shams Maternity HospitalRan2016 to 2016Enrolled166ConditionsPolycystic Ovary Syndrome, Insulin Resistance, Vitamin D Deficiency
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Vitamin D and polycystic ovary syndrome (PCOS): a review.Annals of medicine and surgery (2012) · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lubna PalObstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA. Lubna.pal@yale.edu
Amber Berry
Luisa Coraluzzi
Erin Kustan
Cheryl Danton
Julia Shaw
Hugh Taylor
Yale University · USEmory University · US

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
NCRR NIH HHS UL1 RR024139
6 · The paper itself

Abstract

objectiveTo assess effects of vitamin D and Calcium (Ca) on hormonal and metabolic milieu of polycystic ovary syndrome (PCOS).

designSingle arm open label trial.

methodsTwelve overweight and vitamin D deficient women with PCOS underwent a 2 hour oral glucose tolerance testing at baseline and following 3-month supplementation with vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily.

main outcome measuresBlood pressure (BP), plasma glucose, insulin, total testosterone (T) androstenedione (A), sex hormone binding globulin, lifestyle parameters were assessed at baseline and following 3-month intervention. Insulin resistance (IR) and area under the curve for glucose and insulin were computed; paired analyses were conducted.

resultsImproved serum 25OHD (p < 0.001) and reductions in total T (p = 0.036) and A (p = 0.090) levels were noted following 3-month supplementation, compared to baseline. Significant lowering in BP parameters was seen in participants with baseline BP ≥ 120/80 mmHg (n = 8) and in those with baseline serum 25OHD ≤20 ng/ml (n = 9). Parameters of glucose homeostasis and IR remained unchanged (p > 0.05).

conclusionsAndrogen and BP profiles improved followed three month intervention, suggesting therapeutic implications of vitamin D and Ca in overweight and vitamin D deficient women with PCOS.

Indexed as

Dietary Supplements25-Hydroxyvitamin D 2AdultBody Mass IndexCalcifediolCalcium, DietaryCholecalciferolCohort StudiesErgocalciferolsFemaleHumansHyperandrogenismHypertensionOverweightPatient DropoutsPilot Projects25-Hydroxyvitamin D 2CalcifediolCalcium, DietaryCholecalciferolErgocalciferolsTestosterone Congeners

Identifiers

PMID22780885
PMCPMC3743962
OpenAlexW2037986775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.